Myriad Genetics Unveils Commercialization Plan for MRD Test

Myriad Genetics Inc. (MYGN) announced on January 27, 2026, its commercial strategy for its Precise MRD assay, a blood test designed to detect minimal residual disease in cancer patients. The company outlined plans for a phased rollout, targeting initial availability through its CLIA laboratory. The test is intended to help physicians monitor treatment response and detect cancer recurrence earlier than traditional methods. Myriad anticipates the assay will support personalized treatment decisions and expand its oncology portfolio, though specific financial projections and launch timelines were not disclosed.